Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

TK Kvien; A Deodhar; L Gossec; PG Conaghan; V Strand; M Østergaard; N Williams; B Porter; K Gandhi; S Jugl

doi:10.1136/annrheumdis-2017-eular.1839

Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

TK Kvien, A Deodhar, L Gossec, PG Conaghan, V Strand, M Østergaard, N Williams, B Porter, K Gandhi, S Jugl

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

239 Citationer (Scopus)

Originalsprog	Engelsk
Artikelnummer	THU0393
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	76
Udgave nummer	Suppl 2
Sider (fra-til)	355-356
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2017-eular.1839
Status	Udgivet - 2017

Adgang til dokumentet

10.1136/annrheumdis-2017-eular.1839

Citationsformater

Kvien, TK., Deodhar, A., Gossec, L., Conaghan, PG., Strand, V., Østergaard, M., Williams, N., Porter, B., Gandhi, K., & Jugl, S. (2017). Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies. Annals of the Rheumatic Diseases, 76(Suppl 2), 355-356. [THU0393]. https://doi.org/10.1136/annrheumdis-2017-eular.1839

Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years : long-term results of two randomised double-blind placebo-controlled phase 3 studies. / Kvien, TK; Deodhar, A; Gossec, L; Conaghan, PG; Strand, V; Østergaard, M; Williams, N; Porter, B; Gandhi, K; Jugl, S.

I: Annals of the Rheumatic Diseases, Bind 76, Nr. Suppl 2, THU0393, 2017, s. 355-356.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Kvien, TK, Deodhar, A, Gossec, L, Conaghan, PG, Strand, V, Østergaard, M, Williams, N, Porter, B, Gandhi, K & Jugl, S 2017, 'Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies', Annals of the Rheumatic Diseases, bind 76, nr. Suppl 2, THU0393, s. 355-356. https://doi.org/10.1136/annrheumdis-2017-eular.1839

Kvien TK, Deodhar A, Gossec L, Conaghan PG, Strand V, Østergaard M et al. Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies. Annals of the Rheumatic Diseases. 2017;76(Suppl 2):355-356. THU0393. https://doi.org/10.1136/annrheumdis-2017-eular.1839

Kvien, TK ; Deodhar, A ; Gossec, L ; Conaghan, PG ; Strand, V ; Østergaard, M ; Williams, N ; Porter, B ; Gandhi, K ; Jugl, S. / Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years : long-term results of two randomised double-blind placebo-controlled phase 3 studies. I: Annals of the Rheumatic Diseases. 2017 ; Bind 76, Nr. Suppl 2. s. 355-356.

@article{e87a1335c606472e9b009dfb52f4d5f3,

title = "Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies",

author = "TK Kvien and A Deodhar and L Gossec and PG Conaghan and V Strand and M {\O}stergaard and N Williams and B Porter and K Gandhi and S Jugl",

year = "2017",

doi = "10.1136/annrheumdis-2017-eular.1839",

language = "English",

volume = "76",

pages = "355--356",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years

T2 - long-term results of two randomised double-blind placebo-controlled phase 3 studies

AU - Kvien, TK

AU - Deodhar, A

AU - Gossec, L

AU - Conaghan, PG

AU - Strand, V

AU - Østergaard, M

AU - Williams, N

AU - Porter, B

AU - Gandhi, K

AU - Jugl, S

PY - 2017

Y1 - 2017

U2 - 10.1136/annrheumdis-2017-eular.1839

DO - 10.1136/annrheumdis-2017-eular.1839

M3 - Conference abstract in journal

VL - 76

SP - 355

EP - 356

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - Suppl 2

M1 - THU0393

ER -